EGFR过表达和EGFR基因扩增与胶质母细胞瘤预后关系的Meta分析

EGFR overexpression and EGFR amplification in the prognosis of GBM:A meta-analysis

目的：探讨表皮生长因子受体（EG-FR）过表达和EGFR基因扩增对胶质母细胞瘤（GBM）预后的影响。方法：以相对危险比（RH）为效应统计量,应用Meta分析方法对有关EGFR过表达和EGFR扩增与GBM预后的文献进行定量综合分析。结果：纳入的12篇文献。研究EGFR过表达的文献7篇,累计病例626例,阳性率为52.9%;研究EGFR扩增的6篇,累计病例433例,阳性率为33.5%。EGFR过表达与GBM预后关系的合并相对危险比（RH）及95%可信区间（CI）分别为1.06和0.73~1.53;EGFR扩增与GBM预后关系的合并RH及95%CI分别为1.11和0.81~1.53。结论：EGFR过表达和EGFR扩增可能均与GBM预后无关。

OBJECTIVE： To investigate the correlation of EGFR overexpression and EGFR amplification with the prognosis of GBM.METHODS： The literatures on the correlation of EGFR overexpression and EGFR amplification with the prognosis of GBM were analyzed by Meta-analysis method.Relative hazard（RH） was applied to evaluate the risk of disease.RESULTS： A total of twelve studies were identified,including seven studies of 626 patients（positive rate of 52.9%） on EGFR overexpression and six studies of 433 cases（positive rate of 33.5%） on EGFR amplification.The combined RH of EGFR overexpression on the prognosis of GBM was 1.06 and 95%CI was 0.73-1.53,while the combined RH of EGFR mutations on the prognosis of GBM was 1.11 and 95%CI was 0.81-1.53,respectively.CONCLUSION： Both EGFR overexpression and amplification have no correlation with prognosis of GBM.